Lipton RB, Halker Singh RB, Mechtler L, McVige J, et al. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial. Cephalalgia 2023;51:3331024231190296.
PMID: 37638400